Lixte Biotechnology (LIXT) Short Interest Ratio & Short Volume

Short interest is the volume of Lixte Biotechnology shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 82,700 shares of LIXT short. 4.59% of Lixte Biotechnology's shares are currently sold short. Learn More on Lixte Biotechnology's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.59% of Lixte Biotechnology's floating shares are currently sold short.

Lixte Biotechnology saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 82,700 shares, an increase of 395.2% from the previous total of 16,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lixte Biotechnology currently has issued a total of 2,250,000 shares. Some of Lixte Biotechnology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lixte Biotechnology currently has a public float of 1,800,000 shares.

4.59% of Lixte Biotechnology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Lixte Biotechnology: ASLAN Pharmaceuticals Limited (1.47%), Biofrontera Inc. (1.20%), TFF Pharmaceuticals, Inc. (2.77%), Bionomics Limited (2.03%), Chemomab Therapeutics Ltd. (1.31%), Pasithea Therapeutics Corp. (1.34%), Kineta, Inc. (1.23%), Hepion Pharmaceuticals, Inc. (1.19%), Cyclerion Therapeutics, Inc. (1.03%), Virios Therapeutics, Inc. (1.11%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling LIXT is an investing strategy that aims to generate trading profit from Lixte Biotechnology as its price is falling. LIXT shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lixte Biotechnology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LIXT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LIXT, twice per month. The most recent reporting period available is April, 15 2024.